Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes : Episode 13
Patient Factors Considered when Choosing Treatment Selection
Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.
EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC
EP: 2.The Impact of Molecular Testing on Treatment Choices for NSCLC
EP: 3.Overview of FLAURA and MARIPOSA-2 Clinical Trials
EP: 4.Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
EP: 5.Factors in Selecting Treatment Options for EGFR+ NSCLC
EP: 6.Evaluating Treatment Options of EGFR Inhibitors
EP: 7.Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices
EP: 8.Jason’s Journey with ALK+ Metatstatic NSCLC
EP: 9.Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
EP: 10.Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
EP: 11.Overview of Current Treatment Landscape of ALK Inhibitors
EP: 12.Clinical Experience of Lorlatinib ALK+ NSCLC Patients
Now Viewing
EP: 13.Patient Factors Considered when Choosing Treatment Selection
EP: 14.Treatment Strategies in Disease Progression in ALK+ NSCLC
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
- Dr.Thawani asks Dr Garon:How do you approach choosing between the different ALK inhibitors available?
- What factors guide your selection, and in which cases might you prefer alectinib, lorlatinib, or brigatinib?
Recent Videos
